Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0181 -0.0121 (-40.07%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Granted Important New Oral Nicotine Patent
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
Via CannabisNewsWire
Lexaria Provides Annual Letter From the CEO
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms... 
Via TheNewswire.com
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via CannabisNewsWire
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via CannabisNewsWire
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via CannabisNewsWire
Topics Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via CannabisNewsWire
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
- DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Death Intellectual Property
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.